The Ayurvedic Pharmaceuticals Company Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 05-12-2024
- Paid Up Capital ₹ 1.00 M
as on 05-12-2024
- Company Age 119 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 50.00 K
as on 05-12-2024
- Revenue 70.00%
(FY 2022)
- Profit 440.72%
(FY 2022)
- Ebitda 16047.47%
(FY 2022)
- Net Worth 2.08%
(FY 2022)
- Total Assets 0.64%
(FY 2022)
About The Ayurvedic Pharmaceuticals Company
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company has closed loans amounting to ₹50,000.00, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Ashok Pahwa, Kaushal Pahwa, and Savita Pahwa serve as directors at the Company.
- CIN/LLPIN
U74899DL1905PLC003057
- Company No.
003057
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
02 Jan 1905
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
West Delhi, Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at The Ayurvedic Pharmaceuticals Company?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ashok Pahwa  | Director | 17-Jul-2020 | Current |
| Kaushal Pahwa | Director | 17-Jul-2020 | Current |
| Savita Pahwa | Director | 17-Jul-2020 | Current |
Financial Performance and Corporate Structure Insights of The Ayurvedic Pharmaceuticals Company.
The Ayurvedic Pharmaceuticals Company Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 70% increase. The company also saw a substantial improvement in profitability, with a 440.72% increase in profit. The company's net worth moved up by a moderate rise of 2.08%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of The Ayurvedic Pharmaceuticals Company?
In 2022, The Ayurvedic Pharmaceuticals Company had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Punjab National Bank Creation Date: 17 Jan 1981 | ₹0.05 M | Satisfied |
How Many Employees Work at The Ayurvedic Pharmaceuticals Company?
Unlock and access historical data on people associated with The Ayurvedic Pharmaceuticals Company, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of The Ayurvedic Pharmaceuticals Company, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped The Ayurvedic Pharmaceuticals Company's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
